Oxurion NV — Major Shareholding Notification 2025

Jul 3, 2025

Oxurion Receives Transparency Notifications from Atlas Special Opportunities II LLC

Leuven, BELGIUM – July 3, 2025 – 06:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation¹ it has received transparency notifications as follows:

Oxurion received a transparency notification on July 3, 2025, from Atlas Special Opportunities II, LLC indicating that as of June 27, 2025, it held 394,213 shares of the then outstanding 8,496,303 shares, and therefore crossed under the threshold (5%) by virtue of the selling of voting securities.

Oxurion received a transparency notification on July 3, 2025, from Atlas Special Opportunities II, LLC indicating that as of July 1, 2025, it held 26,211 shares of the then outstanding 8,496,303 shares, and therefore crossed under the threshold (3%) by virtue of the selling of voting securities.

About Oxurion

Oxurion NV (Euronext Brussels: OXUR) is a biopharmaceutical group in transition, combining therapeutic innovation with technologies applied to clinical research. Through its rapidly expanding technology division, Oxurion is building integrated expertise around clinical data, with the ambition to accelerate, secure, and transform the processes involved in developing new treatments. The Group's headquarters are based in Leuven, Belgium. More information is available at www.oxurion.com.

Important information about forward-looking statements

Certain statements in this press release may be considered "forward-looking". Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forwardlooking statement is contained in the Company's Annual Report. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of Oxurion in any jurisdiction. No securities of Oxurion may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. state securities laws.

For further information please contact:

Oxurion NV Pascal Ghoson Chief Executive Officer Pascal.ghoson@oxurion.com

________

1. Article 14, first paragraph, of the Law of 2 May 2007 on disclosure of major holdings.

ANNEX 1

FSMA MARKETS AUTHORITY	FINANCIAL SERVICES AND	Transparency notification Form TR-1 BE PART I
1) Status of the notification
	Final
2) Issuer
Identification number 0881-620-924	Name OXURION
3) Reason for the notification
	Acquisition or disposal of voting securities or voting rights
4) Notification by
	A person that notifies alone
5) Persons subject to the notification requirement
	Name	Address (for legal entitles)
	Atlas Special Opportunities II LLC	2500 Westchester Avenue, Suite 401, Purchase, NY 10577
	6) Persons that dispose of voting rights (only to be filled in if art. 7 of the Law applies)
	Name	Address (for legal entitles)
	Please continue entering the information in part if concerning the persons referred to In Sections 5 and 6	Part II
7) Date on which the threshold is crossed
		27/06/2025 (DD/MM/YYYYY)
8) Threshold that is crossed (in %)
		റ
	If the holding has tallen below the lowest threehold, you have the option of not entering any numbers in Section 10
9) Denominator
	8,496,303
	Please enter the denominator before filling in the data
10) Notified details
A) Voting rights	Previous notification	After the transaction
	# of voting rights	# of voting rights	% of voting rights

B) Equivalent financial instruments	After the transaction
Holders of equivalent financial Instruments	Type of financial Instrument	Expiration diate	Exercise period or date	# of voting rights that may be acquired if the Instrument Is exercised	% of voting rights	Settlement
							+
TOTAL					0.00%
3 The zotals will be updated once you have clicked on «CALCULATE>
TOTAL (A & B)			# of voting rights	% of voting rights

11) Full chain of controlled undertakinos through which the holding is effectively held, if applicable

CALCULATE

394,213

4.64%

12) In case of proxy voting for only one GM

			(DD/MM/YYTY)
Holder	will cease to hold / will hold again	voting rights as of

13) Additional information

On 24 June 2020 (ult settement date of 5 une 2020). All 417,94 than in Oxim N. as a reut on the his haneloling dereased b 277 anner ( 7.3%)
Generi (-4.9%).
On 25 (-1) 4.0%)

	Done at New York
On		01/07/2025 (DD/MM/YYYYY)
	Name & capacity Patrick Vance, Proxyholder		- Signed by: Signature Vation artik varia -9A8C4789B05442E

For security reasons, the unsigned form in xlsx format should
be transmitted to trp.fin@fsma.be. You can do this manally
OR if you have MS Outlook at your disposal via the

In addition, a signed copy in PDF format should also be transmitted.

ANNEX 2

FSMA	FINANCIAL SERVICES AND MARKETS AUTHORITY		Form TR-1 BE PART I	Transparency notification
1) Status of the notification
	Draft
2) Issuer
Identification number 0881-620-924	Name OXURION
3) Reason for the notification
	Downward crossing of the lowest threshold
4) Notification by
	A person that notifies alone
5) Persons subject to the notification requirement
	Name				Address (for legal entitles)
	Atlas Special Opportunities II LLC			2500 Westchester Avenue, Sulte 401, Purchase, NY 10577
6) Persons that dispose of votinq rights (only to be filled in if art. 7 of the Law applies)
	Name				Address (for legal entitles)
0	Please continue entering the information in part it concerning the persons referred to In Sections 5 and 6			Part II
7) Date on which the threshold is crossed
			(YYYYMMIDD) (DD/MM/YYYYY)
8) Threshold that is crossed (in %)
		3
	If the holding has fallen below the lowest threatold, you have the option of not entering any numbers in Section 10
9) Denominator
		8,496,303
	Please enter the denominator before filling in the data
10) Notified details
A) Voting rights	Previous notification			After the transaction
	# of voting rights		# of voting rights	Not linked to the	Linked to	% of voting rights Not linked to the
Holders of voting rights			Linked to securities

B) Equivalent financial instruments	After the transaction
Holders of equivalent financial Instruments	Type of financial Instrument	Expiration date	Exercise period or diate	# of voting rights that may be acquired if the Instrument is exercised	% of voting rights	Settlement
							+
TOTAL			0	0.00%
The rorale will be undated ones you have olloked on <CALCULATEs:

S

TOTAL (A & B)			# of voting rights % of voting rights
	CALCULATE	26,211	0.31%

11) Full chain of controlled undertakings through which the holding is effectively held, if applicable

12) In case of proxy voting for only one GM

Holder	will cease to hold / will hold again	voting rights as of

13) Additional information

On 25 Jim editerial of 27 June 2025, Allas Special Doxicolines II Last 227,50 States Mich is barabildir deserballer de 2021 Stare (- 6.4%)
(Secretare (- 2025), Alas Special C

	Done at New York
On		(1/07/2025 (DD/MM/YYYYY)
	Name & capacity Patrick Vance, Proxyholder		- Signed by: Signature 1 at 18 1 arrive vival -9A8C4789B05442E

For security reasons, the unsigned form in xlsx format should
be transmitted to trp.fin@fsma.be. You can do this manually
OR if you have MS Outlook at your disposal via the " Send" button.

In addition, a signed copy in PDF format should also be
transmitted.